Table 1 Patient demographics and disease characteristics of galcanezumab -treated patients from episodic and chronic migraine trials
Variables | Episodic Migraine Studiesa | Chronic Migraine Studyb | ||
|---|---|---|---|---|
Galanezumaba N = 879 | Placebo N = 894 | Galcanezumabb N = 555 | Placebo N = 558 | |
Age, years, mean (SD) | 40.7 (11.4) | 41.9 (11.4) | 40.4 (12.2) | 41.6 (12.1) |
Female, n (%) | 744 (84.6) | 755 (84.5) | 463 (83.4) | 483 (86.6) |
Race white, n (%) | 652 (74.2) | 681 (76.2) | 447 (80.7) | 432 (77.4) |
Ethnicity not Hispanic or Latinoc, n (%) | 664 (78.4) | 677 (79.4) | 387 (74.0) | 401 (76.7) |
Geographic region, n (%) | ||||
North America | 647 (73.6) | 657 (73.5) | 320 (57.7) | 321 (57.5) |
Europe | 119 (13.5) | 122 (13.7) | 138 (24.9) | 140 (25.1) |
Other | 113 (12.9) | 115 (12.9) | 97 (17.5) | 97 (17.4) |
Body mass index, kg/m2 mean (SD) | 27.6 (5.5) | 27.6 (5.5) | 26.5 (5.4) | 26.9 (5.6) |
Migraine disease duration, years, mean (SD) | 20.1 (12.2) | 20.5 (12.5) | 20.2 (12.7) | 21.9 (12.9) |
Migraine headache days/month, mean (SD) | 9.1 (2.9) | 9.1 (3.0) | 19.3 (4.4) | 19.6 (4.6) |
MHD/month with acute medication use, mean (SD) | 7.4 (3.4) | 7.5 (3.4) | 14.8 (6.3) | 15.5 (6.6) |
Headache days/month, mean (SD) | 10.7 (3.7) | 10.6 (3.4) | 21.3 (4.0) | 21.5 (4.1) |
Migraine with aura, n (%) | 467 (53.1) | 471 (52.7) | 294 (53.0) | 310 (55.6) |
Prior preventive treatment in past 5 years, n (%) | 559 (63.6) | 555 (62.1) | 431 (77.7) | 435 (78.0) |
Failed ≥ 2 preventives in past 5 years, n (%) | 88 (10.0) | 85 (9.5) | 165 (29.7) | 163 (29.2) |
MIDAS total, mean (SD) | 33.1 (28.2) | 33.1 (29.3) | 65.8 (57.3) | 68.7 (57.4) |
MSQ RF-R, mean (SD) | 51.1 (16.1) | 52.1 (15.6) | 39.1 (17.3) | 38.4 (17.2) |
PGI-S, mean (SD) | 4.3 (1.2) | 4.3 (1.2) | 4.8 (1.3) | 4.9 (1.2) |